JP7200093B2 - がん治療用ｔｌｒ９アゴニストを用いた免疫調節 - Google Patents

がん治療用ｔｌｒ９アゴニストを用いた免疫調節 Download PDF

Info

Publication number
JP7200093B2
JP7200093B2 JP2019514720A JP2019514720A JP7200093B2 JP 7200093 B2 JP7200093 B2 JP 7200093B2 JP 2019514720 A JP2019514720 A JP 2019514720A JP 2019514720 A JP2019514720 A JP 2019514720A JP 7200093 B2 JP7200093 B2 JP 7200093B2
Authority
JP
Japan
Prior art keywords
imo
tumor
cancer
administered
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019514720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529415A (ja
JP2019529415A5 (https=
Inventor
アグラワル，スディール
ワン，ダーチン
ジャン，ウェイン
Original Assignee
アイデラ・ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイデラ・ファーマシューティカルズ，インコーポレーテッド filed Critical アイデラ・ファーマシューティカルズ，インコーポレーテッド
Publication of JP2019529415A publication Critical patent/JP2019529415A/ja
Publication of JP2019529415A5 publication Critical patent/JP2019529415A5/ja
Priority to JP2021170043A priority Critical patent/JP2022009200A/ja
Application granted granted Critical
Publication of JP7200093B2 publication Critical patent/JP7200093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019514720A 2016-09-15 2017-09-15 がん治療用ｔｌｒ９アゴニストを用いた免疫調節 Active JP7200093B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021170043A JP2022009200A (ja) 2016-09-15 2021-10-18 がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662394845P 2016-09-15 2016-09-15
US62/394,845 2016-09-15
US201762486738P 2017-04-18 2017-04-18
US62/486,738 2017-04-18
PCT/US2017/051742 WO2018053242A1 (en) 2016-09-15 2017-09-15 Immune modulation with tlr9 agonists for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021170043A Division JP2022009200A (ja) 2016-09-15 2021-10-18 がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Publications (3)

Publication Number Publication Date
JP2019529415A JP2019529415A (ja) 2019-10-17
JP2019529415A5 JP2019529415A5 (https=) 2020-11-05
JP7200093B2 true JP7200093B2 (ja) 2023-01-06

Family

ID=61620152

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019514720A Active JP7200093B2 (ja) 2016-09-15 2017-09-15 がん治療用ｔｌｒ９アゴニストを用いた免疫調節
JP2021170043A Pending JP2022009200A (ja) 2016-09-15 2021-10-18 がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021170043A Pending JP2022009200A (ja) 2016-09-15 2021-10-18 がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Country Status (10)

Country Link
US (6) US10463686B2 (https=)
EP (1) EP3512499A4 (https=)
JP (2) JP7200093B2 (https=)
KR (1) KR20190096936A (https=)
CN (1) CN110114057A (https=)
AU (1) AU2017325981A1 (https=)
CA (1) CA3036978A1 (https=)
IL (2) IL292658A (https=)
MX (1) MX2019002925A (https=)
WO (1) WO2018053242A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US11643463B2 (en) 2017-05-19 2023-05-09 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
JP2022512745A (ja) * 2018-10-18 2022-02-07 アイデラ・ファーマシューティカルズ，インコーポレーテッド がんを処置するためのｔｌｒ９調節因子
KR20210087454A (ko) * 2018-11-01 2021-07-12 파론 파머수티컬스 오와이 대체 활성화되는 대식세포 상의 clever-1 발현을 억제하는데 사용하기 위한 tlr9 작용제
BR112021012536A2 (pt) 2018-12-26 2021-09-14 City Of Hope Proteínas de ligação anti-ctla4 mascaradas ativáveis
US20230072809A1 (en) * 2020-03-09 2023-03-09 Dynavax Technologies Corporation Active booster immunization against tetanus, diphtheria and pertussis
DE112021004970T5 (de) * 2020-09-22 2023-07-06 Trisalus Life Sciences, Inc. Krebstherapie unter verwendung von toll-like-rezeptor-agonisten
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057898A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1200580T3 (da) 1999-08-13 2005-04-11 Hybridon Inc Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
JP4188687B2 (ja) 2000-12-27 2008-11-26 ダイナバックス テクノロジーズ コーポレイション 免疫変調ポリヌクレオチド及びその使用法
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
PT1992635E (pt) * 2002-12-23 2012-03-20 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
MXPA05013658A (es) 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
CN100482673C (zh) 2003-07-15 2009-04-29 艾德拉药物股份有限公司 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用
MXPA06000619A (es) 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
US20060014713A1 (en) 2004-06-15 2006-01-19 Hybridon, Inc. Immunostimulatory oligonucleotide multimers
US7427405B2 (en) 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
JP2009500412A (ja) 2005-07-07 2009-01-08 コーリー ファーマシューティカル グループ，インコーポレイテッド 癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7786089B2 (en) 2005-12-20 2010-08-31 Idera Pharmaceuticals, Inc. Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments
US20080031887A1 (en) 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
MX2009006230A (es) 2006-12-12 2009-06-22 Idera Pharmaceuticals Inc Agonistas sinteticos de receptores de tipo toll 9.
KR20100053598A (ko) 2007-08-01 2010-05-20 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ９의 신규한 합성 효능제
US20110293565A1 (en) 2009-01-30 2011-12-01 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
EP2533779A4 (en) 2010-02-09 2013-08-21 Georgia Health Sciences University Res Inst Inc ALPHA-METHYL-TRYPTOPHANE AS INHIBITORS OF INDOLEAMINE DIOXYGENASE
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
FR2975600B1 (fr) * 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US9308253B2 (en) * 2011-09-19 2016-04-12 The Johns Hopkins University Cancer immunotherapy
CN105163754B (zh) 2012-09-20 2018-01-05 王荣福 前列腺特异性肿瘤抗原及其用途
JP6508785B2 (ja) 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
WO2016030863A1 (en) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
ES3011733T3 (en) * 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
CN107708706A (zh) 2015-05-29 2018-02-16 戴纳瓦克斯技术公司 用于治疗肺的癌症的多核苷酸Toll样受体9激动剂的肺内施用
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057898A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｃａｎｃｅｒ Ｉｍｍｕｎｏｌ． Ｒｅｓ． （Ｊａｎ ２０１６） ｖｏｌ．４， Ｉｓｓｕｅ １ Ｓｕｐｐｌ．， Ａｂｓｔｒａｃｔ Ｂ１５３
Ｍｏｄｕｌａｔｉｏｎ ｏｆ Ｃｈｅｃｋｐｏｉｎｔ Ｅｘｐｒｅｓｓｉｏｎ ｉｎ Ｔｕｍｏｒ Ｍｉｃｒｏｅｎｖｉｒｏｎｍｅｎｔ ｂｙ Ｉｎｔｒａｔｕｍｏｒａｌ Ａｄｍｉｎｉｓｔｒａｔｉｏｎ ｏｆ ａ Ｎｏｖｅｌ ＴＬＲ９ Ａｇｏｎｉｓｔ： Ｒａｔｉｏｎａｌｅ ｆｏｒ Ｃｏｍｂｉｎａｔｉｏｎ Ｔｈｅｒａｐｙ， ＣＲＩ－ＣＩＭＴ－ＥＡＴＩ－ＡＡＣＲ Ｔｈｅ Ｉｎａｕｇｕｒａｌ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｃａｎｃｅｒ Ｉｍｍｕｎｏｔｈｅｒａｐｙ Ｃｏｎｆｅｒｅｎｃｅ， Ｎｅｗ Ｙｏｒｋ， ＮＹ， Ｓｅｐｔｅｍｂｅｒ １６－１９， ２０１５， ［ｒｅｔｒｉｅｖｅｄ ｏｎ ２０２０－１２－０３］， ＜ｈｔｔｐｓ：／／ｗｗｗ．ｉｄｅｒａｐｈａｒｍａ．ｃｏｍ／ｗｐ－ｃｏｎｔｅｎｔ／ｕｐｌｏａｄｓ／２０１５／０９／ｉｄｅｒａ＿ａａｃｒ＿２０１５＿ｃｈｅｃｋｐｏｉｎｔ＿ｆｉｎａｌ．ｐｄｆ＞
ＮＣＴ０２６４４９６７ Ａ Ｓｔｕｄｙ ｔｏ Ａｓｓｅｓｓ ｔｈｅ Ｓａｆｅｔｙａｎｄ Ｅｆｆｉｃａｃｙ ｏｆ Ｉｎｔｒａｔｕｍｏｒａｌ ＩＭＯ－２１２５ ｉｎ Ｃｏｍｂｉｎａｔｉｏｎ Ｗｉｔｈ Ｉｐｉｌｉｍｕｍａｂ ｏｒＰｅｍｂｒｏｌｉｚｕｍａｂ ｉｎ Ｐａｔｉｅｎｔｓ Ｗｉｔｈ Ｍｅｔａｓｔａｔｉｃ Ｍｅｌａｎｏｍａ， ＣｌｉｎｉｃａｌＴｒｉａｌｓ．ｇｏｖ， ［ｏｎｌｉｎｅ］，２０１６－０６－０２， ［ｒｅｔｒｉｅｖｅｄ ｏｎ ２０２０－１２－０３］， ＜ｈｔｔｐｓ：／／ｃｌｉｎｉｃａｌｔｒｉａｌｓ．ｇｏｖ／ｃｔ２／ｈｉｓｔｏｒｙ／ＮＣＴ０２６４４９６７？Ｖ＿４＝Ｖｉｅｗ＃ＳｔｕｄｙＰａｇｅＴｏｐ＞

Also Published As

Publication number Publication date
EP3512499A4 (en) 2020-08-05
US20180125877A1 (en) 2018-05-10
US11224611B2 (en) 2022-01-18
US10835550B2 (en) 2020-11-17
JP2022009200A (ja) 2022-01-14
JP2019529415A (ja) 2019-10-17
KR20190096936A (ko) 2019-08-20
IL292658A (en) 2022-07-01
US10772907B2 (en) 2020-09-15
IL265370B (en) 2022-06-01
MX2019002925A (es) 2019-09-05
US20210038630A1 (en) 2021-02-11
CA3036978A1 (en) 2018-03-22
US20210052625A1 (en) 2021-02-25
AU2017325981A1 (en) 2019-04-11
WO2018053242A1 (en) 2018-03-22
US20200054663A1 (en) 2020-02-20
EP3512499A1 (en) 2019-07-24
CN110114057A (zh) 2019-08-09
US20220088054A1 (en) 2022-03-24
US10463686B2 (en) 2019-11-05
IL265370A (en) 2019-05-30
US20200138848A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7200093B2 (ja) がん治療用ｔｌｒ９アゴニストを用いた免疫調節
US20230374503A1 (en) Combination
KR102333658B1 (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
JP2021529741A (ja) がん治療
WO2022166909A1 (en) Use of ppar-delta inhibitor in combination with immunotherapeutic drug for preparing anti-tumor drug
KR20180015269A (ko) 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
WO2018075447A1 (en) Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
CN113677402A (zh) 治疗肿瘤的方法
JP2023539436A (ja) 膵臓癌の評価および処置のための方法および組成物
US20190083556A1 (en) Analytical methods and arrays for use in the same
HK40058967A (en) Tlr9 modulators for treating cancer
CN113226366A (zh) 用于治疗癌症的tlr9调节剂
HK1238287B (en) Combination
HK1238287A1 (en) Combination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200915

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200928

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211018

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211018

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211112

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211217

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211221

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221017

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221115

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221208

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221221

R150 Certificate of patent or registration of utility model

Ref document number: 7200093

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150